1. Home
  2. ISPO vs MAIA Comparison

ISPO vs MAIA Comparison

Compare ISPO & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ISPO

Inspirato Incorporated

HOLD

Current Price

$4.25

Market Cap

53.4M

Sector

Finance

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.76

Market Cap

49.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ISPO
MAIA
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.4M
49.3M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
ISPO
MAIA
Price
$4.25
$1.76
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
170.4K
622.1K
Earning Date
02-23-2026
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$247,652,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$156.55
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.19
$0.87
52 Week High
$7.17
$2.74

Technical Indicators

Market Signals
Indicator
ISPO
MAIA
Relative Strength Index (RSI) 85.02 63.20
Support Level $4.18 $1.49
Resistance Level $4.20 $1.71
Average True Range (ATR) 0.02 0.14
MACD -0.04 0.01
Stochastic Oscillator 100.00 76.79

Price Performance

Historical Comparison
ISPO
MAIA

About ISPO Inspirato Incorporated

Inspirato Inc is a private, luxury hospitality club that provides its members with access to an exclusive portfolio of high-end vacation homes, luxury hotels, and curated travel experiences worldwide. The club offers personalized service, dedicated trip planning, and seamless access to exceptional properties through its innovative model designed to ensure the service, certainty and value that discerning customers demand. The Inspirato portfolio of curated luxury vacation options includes approximately 350 private luxury vacation homes and accommodations at over 220 luxury hotel and resort partners in over 180 destinations around the world.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: